Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
50%
Ph phase_4
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

completed150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_4

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

NCT05916911
completedphase_2

Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal

NCT03584308

Clinical Trials (2)

Showing 2 of 2 trials
NCT05916911Phase 4

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Recruiting
NCT03584308Phase 2

Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal

Completed

All 2 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
2